ÂÜÀòÂÒÂ×

Erik Hedner has extensive work experience in the field of drug development and regulatory affairs. Erik is currently working as the Director of Drug Development at Arex Advisor since July 2020. Before that, they held the position of Senior Regulatory Affairs Specialist at Mucocort AB from January 2020 to July 2020. Prior to that, they worked as the Director of Drug Development at ProPharma Group from July 2018 to January 2020. Erik also had significant roles at Sofus Regulatory Affairs AB, where they served as the Director of Drug Development from September 2016 to July 2018, and as a Regulatory Affairs Development Consultant from March 2014 to September 2016. Erik began their career at Läkemedelsverket, where they worked as a Chemical and Pharmaceutical Assessor from September 2011 to March 2014, and also from January 2008 to September 2011. Overall, Erik Hedner has demonstrated expertise and experience in various roles within the drug development and regulatory affairs field.

Erik Hedner completed their education at Uppsala University. Erik obtained a Master's degree in Business and Economics from 2005 to 2011. Prior to that, they earned a Doctor of Pharmacy (Pharm.D.) degree in Pharmacognosy/Medicinal Chemistry from 2002 to 2007. Additionally, Erik received a Master's degree in Pharmacy from 1996 to 2002.